WCG Acquires Intrinsic Imaging
WCG has announced the acquisition of Intrinsic Imaging, a global provider of medical imaging core lab services. With over a decade of experience, a team of more than 500 board-certified physicians and comprehensive services in support of drug, medical device and artificial intelligence clinical trials, Intrinsic Imaging supports WCG’s scientific and regulatory capabilities, complementing the Company’s suite of solutions.
Moving forward, Intrinsic Imaging will be known as WCG Intrinsic Imaging. The organization will retain its leadership structure and continue to operate from its Bolton, Massachusetts headquarters.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
